EVMN earnings: next report 2026-10-16, real EPS beat/miss history, analyst consensus Buy, P/E -4.77. Updated 2026-07-23.
Evommune (EVMN) Research Hub
Evommune (EVMN) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 10.54 USD (-2.77%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.77, market cap 0.16B. This hub links to the full technical, earnings and options research available for EVMN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 10.54 USD (-2.77%) |
| 52-week range | 10.3 USD – 25.87 USD |
| Trend regime | Range |
| 14-day RSI | 29.1 (Oversold) |
| Trailing P/E | -4.77 |
| Market cap | 0.16B |
| Dividend yield | 0.00% |
| Next earnings | 2026-10-16 |
Available research for EVMN
Covered Call on EVMN: how it works, illustrative setup around the real 10.54 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EVMN: how it works, illustrative setup around the real 10.54 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EVMN: how it works, illustrative setup around the real 10.54 USD price, max profit/loss, breakeven and when to use it. Educational.
EVMN technical analysis: range, last 10.54 USD, RSI 29.1, 52w range 10.3 USD–25.87 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is EVMN in?
Evommune (EVMN) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is EVMN in an uptrend or downtrend?
As of 2026-09-11, EVMN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EVMN's trailing P/E ratio?
EVMN's trailing P/E is -4.77, with a market cap of 0.16B. See the earnings research page for full valuation detail.
When does EVMN next report earnings?
EVMN is next scheduled to report earnings on 2026-10-16, with a consensus EPS estimate of -0.82 USD.